Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D

TUESDAY, May 24, 2022 -- For patients with type 2 diabetes (T2D) receiving first-line sodium-glucose cotransporter-2 inhibitors (SGLT-2i), the risk for stroke, myocardial infarction (MI), and all-cause mortality is similar to those receiving...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news